Skip to search formSkip to main contentSkip to account menu

bleomycin/cytarabine/methotrexate/vincristine

Known as: ARA-C/BLEO/MTX/VCR, CytaBOM 
National Institutes of Health

Related topics

Related topics

4 relations
BleomycinCytarabineMethotrexateVincristine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
The Significance of Bone Marrow Involvement in Aggressive Lymphomas: A Retrospective Comparison of Clinical Outcomes between Peripheral T Cell Lymphoma and Diffuse Large B Cell Lymphoma in China
Background: Peripheral T cell lymphomas (PTCL) have been demonstrated to have a poorer prognosis than diffuse large B cell… 
2006
2006
A phase II trial of promace‐cytabom in previously untreated non‐hodgkin's lymphoma of intermediate‐ or high‐grade histology
Between November 1985 and June 1989 the aggressive combination chemotherapy programme ProMACE‐CytaBOM was used at a community… 
Highly Cited
1999
Highly Cited
1999
The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus—related systemic non‐Hodgkin lymphoma
The International Prognostic Index (IPI) effectively separates aggressive lymphomas into four groups with significantly different… 
1999
1999
Adult non-Hodgkin's lymphoma.
  • I. Mehdi
  • JPMA. The Journal of the Pakistan Medical…
  • 1999
  • Corpus ID: 37028344
1998
1998
A phase I trial of high dose ProMACE-CytaBOM with granulocyte colony stimulating factor for patients with non-Hodgkin's lymphoma.
We hypothesized that the conventional ProMACE-CytaBOM regimen could be improved by administering all drugs on d1 with the S-phase… 
1998
1998
Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype.
Long-lasting results achieved in 54 patients with aggressive non-Hodgkin lymphoma treated with Pro-MACE-CytaBOM regimen were… 
1996
1996
Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM.
PURPOSE The aim of this study was to determine the maximum-tolerated dose (MTD) of cyclophosphamide, doxorubicin, etoposide… 
1995
1995
Effects of rhG-CSF on infection complications and impaired function of neutrophils secondary to chemotherapy for non-Hodgkin's lymphoma. Hokkaido Study Group of Malignant Lymphoma, and rhG-CSF, Japan…
It has been previously demonstrated that the administration of recombinant human granulocyte-colony stimulating factor (rhG-CSF… 
1989
1989
ProMACE-CytaBOM: combination chemotherapy for diffuse large cell lymphoma.
ProMACE CytaBOM, a polychemotherapy regimen consisting of cyclophosphamide, doxorubicin, etoposide cytozar, bleomycin… 
1988
1988
Leukemia of non-T lineage natural killer cells
An unusual case of an aggressive leukemia of natural killer (NK) cells occurred in a 65-year-old male. Clinical characteristics… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)